Novartis AG’s self-proclaimed hit in the Natalee trial with the breast cancer drug Kisqali was always going to be about the details. Late-breaking results presented at the American Society of Clinical Oncology annual meeting suggest that the Swiss group will have to fight hard to grab share from Eli Lilly and Company and its incumbent Verzenio, and to justify an immediate expansion into new patient groups.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?